Head and Neck Cancer (HNC)

$ 8.690,00

Head and Neck Cancer (HNC)

The Head and Neck Cancer (HNC) HNC represents multiple anatomical sites in the head and neck region, includes cancers of the lip and oral cavity, pharynx (nasopharynx, oropharynx, and hypopharynx), and larynx. In the G7 mature markets, Hoffmann-Krueger epidemiologists expect the incident cases of HNC cancer to increase from 135 745 cases in 2012 to 133 410 cases in 2022.

  • Countries concerned :

Add to my wishlist

Scope: G7 Mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK)

10-year patient population forecast + 5 years of historical data


Key Users:  Oncology Market Research - New Product Planning - Business Development & Licensing

Oncology Market Access – Oncology Marketing leaders


Insight: Insight into the Head and Neck cancer strategy and business development activities

Transparent forecasts methodology and assumptions

Concise and comparable analysis


Key epidemiology assumptions are included to give accurate sizing of patient population, epidemiology forecast, key drivers of patient shares.


The oncology drug market is one of the fastest-growing markets in the pharmaceutical industry. The treatment of cancer has shifted away from mass market blockbuster drugs toward a more focused attack on the disease with targeted therapies.


Reasons To Buy


Hoffmann-Krueger ECF (Epidemiology Cancer Forecast) rich data set and easy-to-use tool allow you to focus on cancer subpopulation segment of interest. Hoffmann-Krueger  ECF (Epidemiology Cancer Forecast) giving the opportunity to use epidemiological projections of key oncology patient population.

  • Country : Japan | Germany | United States | Spain | Italy | France | United Kingdom
  • Cancer Type : HNC
  • File : xls